Emergent Biosolutions Gross Margin 2007-2021 | EBS

Current and historical gross margin for Emergent Biosolutions (EBS) over the last 10 years. The current gross profit margin for Emergent Biosolutions as of September 30, 2021 is %.
Emergent Biosolutions Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2021-09-30 $1.65B $1.03B 62.07%
2021-06-30 $1.71B $1.07B 62.32%
2021-03-31 $1.71B $1.16B 68.00%
2020-12-31 $1.56B $1.03B 66.32%
2020-09-30 $1.33B $0.87B 65.57%
2020-06-30 $1.26B $0.81B 64.52%
2020-03-31 $1.11B $0.69B 62.27%
2019-12-31 $1.11B $0.67B 60.85%
2019-09-30 $1.02B $0.60B 59.19%
2019-06-30 $0.88B $0.50B 57.11%
2019-03-31 $0.86B $0.50B 57.83%
2018-12-31 $0.78B $0.46B 58.75%
2018-09-30 $0.71B $0.44B 61.61%
2018-06-30 $0.68B $0.44B 64.02%
2018-03-31 $0.56B $0.37B 65.30%
2017-12-31 $0.56B $0.37B 66.67%
2017-09-30 $0.52B $0.36B 69.36%
2017-06-30 $0.51B $0.36B 69.79%
2017-03-31 $0.50B $0.35B 70.38%
2016-12-31 $0.49B $0.36B 74.03%
2016-09-30 $0.48B $0.36B 75.10%
2016-06-30 $0.49B $0.38B 76.88%
2016-03-31 $0.53B $0.42B 78.79%
2015-12-31 $0.49B $0.38B 78.12%
2015-09-30 $0.45B $0.35B 78.44%
2015-06-30 $0.43B $0.34B 78.14%
2015-03-31 $0.41B $0.31B 75.60%
2014-12-31 $0.40B $0.30B 75.00%
2014-09-30 $0.40B $0.30B 74.00%
2014-06-30 $0.35B $0.26B 73.79%
2014-03-31 $0.32B $0.25B 76.78%
2013-12-31 $0.31B $0.25B 80.13%
2013-09-30 $0.31B $0.25B 80.91%
2013-06-30 $0.29B $0.24B 82.58%
2013-03-31 $0.28B $0.23B 83.27%
2012-12-31 $0.28B $0.24B 83.33%
2012-09-30 $0.30B $0.25B 84.75%
2012-06-30 $0.29B $0.24B 84.32%
2012-03-31 $0.31B $0.26B 84.26%
2011-12-31 $0.27B $0.23B 84.31%
2011-09-30 $0.27B $0.22B 82.90%
2011-06-30 $0.28B $0.24B 83.45%
2011-03-31 $0.26B $0.22B 83.72%
2010-12-31 $0.29B $0.24B 83.22%
2010-09-30 $0.24B $0.19B 81.86%
2010-06-30 $0.21B $0.17B 81.07%
2010-03-31 $0.22B $0.18B 82.49%
2009-12-31 $0.24B $0.19B 80.43%
2009-09-30 $0.22B $0.18B 81.11%
2009-06-30 $0.23B $0.19B 80.95%
2009-03-31 $0.20B $0.16B 79.10%
2008-12-31 $0.18B $0.15B 81.01%
2008-09-30 $0.23B $0.19B 80.69%
2008-06-30 $0.22B $0.17B 79.09%
2008-03-31 $0.20B $0.16B 78.00%
2007-12-31 $0.18B $0.14B 77.60%
2007-09-30 $0.18B $0.14B 80.00%
2007-06-30 $0.18B $0.15B 82.58%
2007-03-31 $0.17B $0.14B 84.34%
2006-12-31 $0.15B $0.13B 84.21%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.380B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88